Barsegian Arpine, Botwinick Adam, Reddy Harsha S
Department of Ophthalmology, SUNY Downstate Medical Center, and Department of Ophthalmology, The New York Eye and Ear Infirmary of Mount Sinai, New York, New York, U.S.A.
Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr;34(2):151-154. doi: 10.1097/IOP.0000000000000903.
To characterize the phenylephrine test in ptotic patients to help clinicians perform the test more efficiently.
Adults with involutional ptosis (n = 24, 30 eyes) were assessed with digital photographs for response to topical 2.5% phenylephrine drop instillation. Patient characteristics (age, gender, iris color, dermatochalasis, brow ptosis, and baseline marginal reflex distance-1 [MRD-1] height) were recorded. From the photographs, change in (MRD-1), presence of conjunctival blanching, pupillary dilation, and Hering effect were recorded at specified time intervals, 1 minute to 1 hour after drop placement. Correlations between patient characteristics and measured outcomes were evaluated using analysis of variance, Pearson coefficient, or chi-square tests.
The authors found that 73% of eyes had eyelid elevation with phenylephrine. Of these, 50% reached maximal eyelid elevation by 5 minutes, and 86% by 10 minutes after drop placement, but 14% did not reach maximal MRD-1 until 30 minutes. There is a negative correlation between the maximum MRD-1 and the baseline MRD-1 eyelid height (r = -0.5330, p < 0.01). There is no significant relationship between time to pupillary dilation with either time to max eyelid elevation or max eyelid elevation. No patient characteristic studied affected the likelihood of eyelid response to phenylephrine or presence of Hering effect.
Although most ptotic eyelids demonstrate a response to 2.5% phenylephrine within 10 minutes, there is a subset of patients that respond much later. More ptotic eyelids had greater eyelid elevation with phenylephrine. Pupillary dilation and conjunctival blanching are neither predictive of nor temporally associated with eyelid height elevation. The authors did not identify any patient factors (e.g., dermatochalasis, brow ptosis) that can predict the likelihood of response to phenylephrine.
对睑下垂患者的去氧肾上腺素试验进行特征描述,以帮助临床医生更有效地进行该试验。
对患有退行性睑下垂的成年人(n = 24,30只眼)进行数码拍照,评估其对局部滴注2.5%去氧肾上腺素滴眼液的反应。记录患者特征(年龄、性别、虹膜颜色、皮肤松弛症、眉下垂和基线边缘反射距离-1[MRD-1]高度)。从照片中,在滴药后1分钟至1小时的特定时间间隔记录(MRD-1)的变化、结膜苍白、瞳孔散大及赫林效应的存在情况。使用方差分析、皮尔逊系数或卡方检验评估患者特征与测量结果之间的相关性。
作者发现73%的眼睛使用去氧肾上腺素后出现眼睑抬高。其中,50%在滴药后5分钟达到最大眼睑抬高,86%在10分钟时达到,但14%直到30分钟才达到最大MRD-1。最大MRD-1与基线MRD-1眼睑高度之间存在负相关(r = -0.5330,p < 0.01)。瞳孔散大时间与最大眼睑抬高时间或最大眼睑抬高之间无显著关系。所研究的患者特征均未影响眼睑对去氧肾上腺素反应的可能性或赫林效应的存在。
尽管大多数睑下垂眼睑在10分钟内对2.5%去氧肾上腺素有反应,但有一部分患者反应要晚得多。更多睑下垂眼睑使用去氧肾上腺素后有更大程度的眼睑抬高。瞳孔散大和结膜苍白既不能预测眼睑高度升高,也与眼睑高度升高无时间关联。作者未发现任何可预测对去氧肾上腺素反应可能性 的患者因素(如皮肤松弛症、眉下垂)。